皮质类固醇使用与体重及腰围的长期变化:Lifelines队列研究
基于Lifelines队列81 361名参与者(平均年龄46.3岁,平均BMI 26.0 kg/m2,41%男性,平均随访3.9年),23.8%使用皮质类固醇。新使用皮质类固醇者随访期间体重增加显著多于非使用者(β 0.034 kg/年,P=0.021),局部使用亦相关(β 0.037 kg/年,P=0.017);新系统使用与腰围增加相关(β 0.200 cm/年,P<0.001),停药与腰围减少相关(β -0.078 cm/年,P=0.028)。效应主要在女性和BMI≥25 kg/m2者中观察,短期未见体重诱导效应。
要点
- 新使用皮质类固醇者体重增加显著多于非使用者(β 0.034 kg/年,P=0.021)。
- 新系统使用皮质类固醇与腰围增加相关(β 0.200 cm/年,P<0.001)。
- 停药与腰围减少相关(β -0.078 cm/年,P=0.028),效应多见于女性和超重/肥胖者。
核心结论
- 皮质类固醇使用(包括局部给药形式)与体重和腰围的长期增加相关,尤其在女性和超重或肥胖个体中;停药与腰围减少相关。
研究设计与样本
- Lifelines队列研究,纳入81 361名参与者(平均年龄46.3岁,平均BMI 26.0 kg/m2,41%男性,平均随访3.9年),采用线性回归分析体重和腰围变化;敏感性分析按性别和BMI分层;使用线性混合效应模型在子集中评估开始使用后的短期体重变化。
主要发现
- 研究期间23.8%为皮质类固醇使用者。
- 报告任何新使用皮质类固醇者随访时体重增加显著多于非使用者(β 0.034 kg/年,P=0.021),尤其是开始局部使用者(β 0.037 kg/年,P=0.017)。
- 新系统使用皮质类固醇与腰围增加相关(β 0.200 cm/年,P<0.001)。
- 停用皮质类固醇导致腰围减少(β -0.078 cm/年,P=0.028)。
- 这些效应主要在女性和BMI≥25 kg/m2个体中观察,在男性和BMI<25 kg/m2者中未观察到;开始使用后数周内未观察到短期体重诱导效应。
临床怎么用
- 作者认为,这些发现强调需要仔细评估长期系统性和局部皮质类固醇使用,因为停药可能对某些患者的肥胖相关结局有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The use of corticosteroids (CS) has been associated with higher body mass index (BMI) and waist circumference (WC) in cross-sectional studies. However, longitudinal data are scarce, particularly for locally administered forms. DESIGN: We analyzed weight and waist circumference changes in 81 361 Lifelines Cohort Study participants (mean age 46.3 years, mean BMI 26.0 kg/m2, 41% male, mean follow-up 3.9 years) via linear regression. Sensitivity analyses included stratification by sex and BMI. Short-term weight changes post-start were assessed in a subset using linear mixed-effect models. RESULTS: We found 23.8% CS users during the study period. Individuals reporting any new use of CS gained significantly more weight compared to nonusers at follow-up (β .034 kg/year, P = .021), particularly among those initiating local CS use (β .037 kg/year, P = .017). Use of new systemic CS was associated with increased WC (β .200 cm/year, P < .001). Discontinuation of CS led to decreased WC (β -.078 cm/year, P = .028). These effects were particularly observed in female participants and individuals with BMI ≥25 kg/m2, but not in male participants and those with BMI < 25 kg/m2. Short-term weight-inducing effects of CS were not observed in the weeks after initiation of CS use. CONCLUSION: This study demonstrates that CS use, including locally administered forms, is associated with long-term increases in weight and WC, notably in female individuals and those with overweight or obesity. Discontinuing CS was linked to reductions in WC. These findings underscore the need to carefully assess chronic systemic and local CS use, as discontinuation could benefit obesity-related outcomes in certain patients.
引用
- Mohseni M, van der Valk ES, Van der Hurk MJB, et al. Corticosteroid Use and Long-Term Changes in Weight and Waist Circumference: The Lifelines Cohort Study. J Clin Endocrinol Metab. 2025. PMID: 40308158. doi:10.1210/clinem/dgaf166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。